BlackRock, Inc. 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-06 4:28 pm Purchase | 2024-11-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 8,787,650 10.300% | 548,570 (+6.66%) | Filing |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 8,239,080 9.700% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 8,239,080 9.700% | 1,223,532 (+17.44%) | Filing |
| 2024-01-25 4:59 pm Purchase | 2023-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 7,015,548 8.300% | 2,663,516 (+61.20%) | Filing |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 4,352,032 6.400% | 662,138 (+17.94%) | Filing |
| 2022-02-07 4:41 pm Purchase | 2021-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 3,689,894 7.000% | 1,369,488 (+59.02%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 2,320,406 5.000% | 492,980 (+26.98%) | Filing |
| 2020-09-09 3:52 pm Purchase | 2020-08-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 1,827,426 4.700% | 112,945 (+6.59%) | Filing |